Drugs should be preferred first-choice treatment for ADHD

pharmafile | August 8, 2018 | News story | Research and Development ADHD, adults, amphetmines, children, prescription, ritalin 

Ritalin and other amphetamines should be the preferred first-choice medications for the short-term treatment of ADHD, according to a study published in the Lancet Psychiatry Journal.

The review of ADHD drugs found that all of the medications studied (apart from modafinil in adults) were more efficacious than placebo. The authors of the study argued that methylphenidate, sold under the brand name Ritalin, is the most effective and best tolerated treatment for ADHD in children, while amphetamines were more effective in adults.

The study, which analysed data from 24,000 patients, 14,000 of whom were children, suggests that prescribing habits should change. The authors of the study noted that misconceptions regarding the safety and efficacy of ADHD medications mean that they are often under prescribed.   

David Coghill, professor of child and adolescent psychiatry at the Royal Children’s Hospital in Melbourne, Australia, said: “I think we have quite strong evidence to suggest that — in the UK and many countries outside the US — ADHD is under-recognised and underdiagnosed and if you don’t recognise and diagnose someone you don’t have the option of what treatment they receive.”

He added that “We now have very clear evidence that the brains of children with ADHD are structurally and functionally very different. That results in a wide range of cognitive difficulties, of impulse control, keeping attention. The medication treatments are very effective at improving those functional deficits as well as reducing the core symptoms.”

Louis Goss

Related Content

PureTech Health’s Founded Entity Akili announces positive data from adult ADHD trial

Clinical-stage biotherapeutics company PureTech Health has reported that its Founded Entity Akili, a digital medicine …


BioNTech seek approval for COVID-19 vaccine in children aged 5-11

Children between 5 and 11 years old are to be targeted by BioNTech as the …

Expansion for first FDA-approved video game for ADHD treatment

Akili Interactive has announced the expansion of its prescription video game treatment, EndeavorRx, with the …

Latest content